Objective: To study the feasibility and operative procedures of liver resection in combination with collateral devascularization for treating patients with hepatic cancer complicated by portal hypertension.
Methods: A retrospective analysis was conducted in 45 cases of hepatectomy for hepatic cancer in combination with portaazygous devascularization for portal hypertension from Jan. 1995 to Jan. 2002.
Results: Operative mortality was zero. The absolute survival rate in 1/2, 1, 2, 3, 4, 5, 6, and 7 years was 44/45(97.8%), 30/41(73.2%), 26/36 (72.2%), 13/27(48.1%), 10/19(52.6%), 5/13(38.5%), 1/7(14.3%), 0/2(0) respectively. During hospitalization, refractory ascites occurred in 1 case and hepatorenal syndrome in another. Upper gastrointestinal hemorrhage occurred in 2 cases during the follow-up period. In the 14 patients who died during the follow-up, 9 died of cancer recurrence, 4 of liver function failure, and 1 of upper gastrointestinal hemorrhage.
Conclusion: Hepatectomy in combination with portaazygous devascularization for patients with liver cancer complicated by portal hypertension is safe and feasible.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Liver cancer multiomics reveals diverse protein kinase A disruptions convergently produce fibrolamellar hepatocellular carcinoma.
Nat Commun
December 2024
Laboratory of Cellular Biophysics, The Rockefeller University, New York, NY, USA.
Fibrolamellar Hepatocellular Carcinoma (FLC) is a rare liver cancer characterized by a fusion oncokinase of the genes DNAJB1 and PRKACA, the catalytic subunit of protein kinase A (PKA). A few FLC-like tumors have been reported showing other alterations involving PKA. To better understand FLC pathogenesis and the relationships among FLC, FLC-like, and other liver tumors, we performed a massive multi-omics analysis.
View Article and Find Full Text PDFCase report: Long-term response to a combination of immune checkpoint inhibitors as a single treatment for multiple synchronous cancers: a case study.
Front Immunol
December 2024
Medical Oncology, Institut de Cancérologie Strasbourg Europe (ICANS), Strasbourg, France.
Introduction: Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy by enhancing the antitumor immune response. This case describes an 80-year-old male with synchronous multiple primary malignancies (MPMs), including lung metastatic hepatocellular carcinoma (HCC), and non-small cell lung carcinoma (NSCLC), and brain metastatic urothelial carcinoma, who was treated with dual ICI therapy.
Case Presentation: The patient, with a history of diabetes, hypertension, dyslipidaemia, well-differentiated neuroendocrine duodenal tumors and micronodular exogenous cirrhosis (Child-Pugh class A), presented with a non-invasive bladder carcinoma (pT1N0M0) resected endoscopically in December 2022.
Comparison of models to predict incident chronic liver disease: a systematic review and external validation in Chinese adults.
BMC Med
December 2024
Department of Epidemiology & Biostatistics, School of Public Health, Peking University, 38 Xueyuan Road, Beijing, 100191, China.
Background: Risk prediction models can identify individuals at high risk of chronic liver disease (CLD), but there is limited evidence on the performance of various models in diverse populations. We aimed to systematically review CLD prediction models, meta-analyze their performance, and externally validate them in 0.5 million Chinese adults in the China Kadoorie Biobank (CKB).
View Article and Find Full Text PDFPrevalence of common conditions and associated mortalities of dogs treated at the small animal clinic, Makerere University, Kampala, Uganda.
BMC Vet Res
December 2024
School of Statistics and Planning, Makerere University, Kampala, Uganda.
Background: In developing countries such as Uganda, domestic dogs suffer high burdens of infectious diseases often with high mortalities. Surveillance data on the common diseases and associated mortalities is however scanty. We thus, present results of a retrospective study of common clinical conditions and mortalities of dogs brought for treatment at the small animal clinic, Makerere University, Kampala, Uganda.
View Article and Find Full Text PDFDevelopment of prognostic models for HER2-positive metastatic breast cancer in females: a retrospective population-based study.
BMC Womens Health
December 2024
The Affiliated Lihuili Hospital, Ningbo University, Ningbo, Zhejiang, 315000, China.
Background: This study aimed to construct, evaluate, and validate nomograms for breast cancer-specific survival (BCSS) and overall survival (OS) prediction in patients with HER2- overexpressing (HER2+) metastatic breast cancer (MBC).
Methods: The Surveillance, Epidemiology, and End Results (SEER) database was used to select female patients diagnosed with HER2 + MBC between 2010 and 2015. These patients were distributed into training and validation groups (7:3 ratio).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!